CA
BMRN icon

Crewe Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Crewe Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-250
Closed -$14.9K – 1052
2025
Q4 		$14.9K Hold
250
– – ﹤0.01% 546
2025
Q3 		$13.5K Hold
250
– – ﹤0.01% 574
2025
Q2 		$13.7K Hold
250
– – ﹤0.01% 422
2025
Q1 		$17.7K Hold
250
– – ﹤0.01% 361
2024
Q4 		$16.4K Hold
250
– – ﹤0.01% 376
2024
Q3 		$17.6K Hold
250
– – ﹤0.01% 417
2024
Q2 		$20.6K Hold
250
– – ﹤0.01% 547
2024
Q1 		$21.8K Buy
+250
New +$22.4K ﹤0.01% 478
2023
Q2 		– Sell
-126
Closed -$12.3K – 891
2023
Q1 		$12.3K Hold
126
– – ﹤0.01% 508
2022
Q4 		$13K Sell
126
-74
-37% -$6.95K ﹤0.01% 497
2022
Q3 		$17K Buy
200
+30
+18% +$2.67K ﹤0.01% 500
2022
Q2 		$14K Buy
+170
New +$13.5K ﹤0.01% 508
2020
Q4 		– Sell
-15
Closed -$1K – 470
2020
Q3 		$1K Buy
+15
New +$1.52K ﹤0.01% 558

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crewe Advisors's BMRN Position: Q1 2026 in Review

Crewe Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 250 shares — an estimated $14.9K sold.

Crewe Advisors first reported a position in BMRN in Q3 2020 and held it in 13 quarters. The position peaked at $21.8K in Q1 2024. 557 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Crewe Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Crewe Advisors sold 250 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $14.9K.
  • Crewe Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 13 quarters.
  • Crewe Advisors's BioMarin Pharmaceuticals position peaked at $21.8K in Q1 2024.
  • 557 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Crewe Advisors's 13F filing for Q1 2026, filed 7 May 2026.